| Date | Title | Description | |
|---|---|---|---|
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
| 21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
| 21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 28 Jul 2021 | On business and financial situation | The company releases the press release related to first half 2021 financial results | Download |
| 28 Jul 2021 | On business and financial situation | ROVI releases the first half 2021 results presentation | Download |
| 05 Jul 2021 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2021 | Download |
| 02 Jul 2021 | Other relevant information | The Company informs about the dividends payment | Download |
| 02 Jul 2021 | Other relevant information | The Company informs about the dividends payment | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
| 21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
| 24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |